PLOS One flags concerns in a breast cancer lectin paper after publication
PLOS One has posted an Editorial Note on a 2014 breast cancer study after concerns were raised about results shown in Figure 7B of the paper. The notice is brief, but its clinical and scientific significance is not: once a result is questioned at the figure level, readers can no longer treat the full experimental claim as settled without checking the underlying data carefully.
The article under review examined whether Sclerotium rolfsii lectin inhibited proliferation more strongly in human breast cancer cells than in normal human mammary epithelial cells, with apoptosis presented as the proposed mechanism. The paper was originally framed around a biologically plausible cancer-selective effect, a familiar ambition in oncology research where many compounds appear potent in malignant cells but prove less selective than hoped in normal tissue. A claim like that depends heavily on clean figure presentation, because the difference between a selective antitumor signal and a misleading artifact may sit inside a single panel.
PLOS One did not describe the exact nature of the concern in the public notice. It identified the affected figure and linked readers back to the original 2014 article, leaving the specific issue to be interpreted through the journal’s editorial process and any later updates. Even without further detail, a figure-level concern in a mechanistic cancer paper carries obvious weight. Apoptosis assays, proliferation curves, and microscopy panels often do more than illustrate the message; they supply the message itself.
Why a figure concern matters in apoptosis-driven cancer research
In cell biology, image-based and panel-based data carry an outsized burden. A Western blot, a microscopy image, a flow-cytometry plot, or a bar graph may appear to be one element of a larger narrative, but the paper’s central conclusion can rise or fall on the integrity of that single display. When a study argues that a lectin induces stronger growth inhibition in breast cancer cells than in normal mammary epithelial cells, readers are not just looking for a statistical difference. They are looking for evidence that the effect is reproducible, selectively directed at tumor cells, and supported across assays.
The biology behind the original claim was straightforward enough. If a compound triggers apoptosis in malignant breast cells while sparing normal epithelial cells to a greater degree, that pattern would support therapeutic interest. Selective cytotoxicity is a core goal in oncology because it offers the possibility of attacking cancer without causing the same degree of collateral damage to healthy tissue. But selectivity is also one of the hardest claims to defend. A cell line result can be influenced by dose selection, exposure time, assay conditions, or image interpretation, and any weakness in the visual record weakens confidence in the entire mechanistic story.
One concern in a figure can change the reading of an entire paper.
That is especially true when the figure is tied to a pivotal mechanistic claim rather than a peripheral control. If Figure 7B supported the apoptosis argument, then any unresolved question about that panel touches the paper’s central interpretation, not just its presentation polish. In oncology journals, editorial notes like this usually signal that readers should approach the original findings with caution while the journal decides whether more action is needed.
The limits of a brief editorial notice
The public notice does not provide a full investigation report, and it does not replace the underlying article. It simply alerts readers that concerns have been raised. That kind of notice leaves several scientific questions unanswered: whether the problem affects image authenticity, figure assembly, labeling, duplication, quantification, or another aspect of the dataset; whether the issue is confined to one panel or extends to connected experiments; and whether the study’s broader conclusions remain intact after review.
For clinicians and translational researchers, the practical consequence is straightforward. The original paper should no longer be cited as though every result stands unchallenged. The title’s central claim, that Sclerotium rolfsii lectin shows stronger inhibition of proliferation in breast cancer cells than in normal mammary epithelial cells through apoptosis, now sits under an editorial caution flag. That does not automatically invalidate the work, but it does mean the evidence base has become less secure.
This kind of post-publication note also reflects a broader reality in preclinical oncology: early-stage findings often travel far ahead of the evidence that supports them. A promising mechanism, an attractive natural product, or a selective antiproliferative signal can gain attention quickly, yet the scientific value of the result depends on whether the figures are reliable enough to anchor downstream experimentation. When a journal intervenes years after publication, it reminds readers that the archive is not frozen. Papers can acquire a different meaning after scrutiny, especially when the signal rests on visual data.
What this means for interpreting the 2014 breast cancer study
The safest reading of the situation is narrow. The journal has formally disclosed concerns about Figure 7B. The paper remains accessible, and the editorial note does not, by itself, state that the article has been retracted or corrected. Still, the presence of a concern changes the clinical-research posture of the work. It moves the paper from a straightforward citation into a piece of literature that requires caution, comparison with other studies, and attention to any future editorial action.
For researchers studying anti-cancer lectins, the episode is a reminder to look beyond a single mechanistic panel when judging biological plausibility. Reproducibility across assays, clean image provenance, and transparent quantification matter as much as the headline effect. A compound that appears to induce apoptosis in breast cancer cells may still be worth further study, but only if the supporting data can withstand post-publication scrutiny.
For readers following this area of oncology, the unresolved issue is not the concept of lectin-mediated cytotoxicity itself. The issue is whether the specific result presented in Figure 7B can be trusted as part of the evidentiary chain for the paper’s main claim. Until that is clarified, the study should be treated as an article under editorial review rather than a settled demonstration of selective anticancer activity.